Dec. 11, 2025 — Telix Pharmaceuticals Ltd. has announced a strategic clinical collaboration with Varian, a Siemens Healthineers company, to develop novel clinical applications that combine Telix's theranostic products and external beam radiation therapy (EBRT).

Dec. 9, 2025 — NVision Imaging Technologies, developer of quantum technology enabling imaging of cell metabolism through MRIs, announced that Memorial Sloan Kettering Cancer Center (MSK) is using its device, Polaris, in oncological preclinical studies. This marks the first use of NVision’s technology at a leading cancer research institution to monitor treatment efficacy in targeted therapies.

Dec. 1, 2025 — Researchers at the University of California, Berkeley and University of California, San Francisco have released Pillar (Pillar-0), an open-source AI model that analyzes medical images and recognizes conditions with an unprecedented degree of diagnostic accuracy. Unlike existing tools that are limited to a handful of conditions or models primarily designed for 2D images, Pillar-0 interprets 3D volumes directly and can recognize hundreds of conditions from a single CT or MRI exam.

Dec. 5, 2025 — Virtual Phantoms Inc. has launched VirtualDose DX — the company’s latest innovation in radiation dose estimation, now applied to diagnostic radiography. VPI has developed industry leading software products VirtualDoseCT for CT and VirtualDoseIR for interventional radiology dose estimation. VirtualDoseDX leverages the same validated Monte Carlo–based technology, extending our dose estimation expertise to radiographic (X-ray) exams.

Nov. 30, 2025 – Ascend Cardiovascular, a provider of purpose-built enterprise imaging for cardiology, and Konica Minolta Healthcare Americas, Inc., a provider of medical diagnostic imaging and healthcare IT solutions, have announced a strategic partnership to deliver a unified and complete enterprise imaging solution for hospital cardiology departments and cardiology practices.

Dec. 09, 2025 — Alpha Tau Medical Ltd., the developer of the alpha-radiation cancer therapy Alpha DaRT recently announced that the first patient has been treated in its pilot study for the treatment of patients with recurrent glioblastoma multiforme (GBM) using the Alpha DaRT technology.

AI Impacts Precision Oncology

Genomics has guided personalized cancer treatments for the past two decades. Now, AI biomarkers are expanding the field, helping radiologists and radiation oncologists stratify risk and potentially plan more precise treatments.

Unlike traditional biomarkers, “AI analyzes images of a patient’s biopsy to predict how aggressive a patient’s cancer might be, or whether they may respond better to treatment A or treatment B,” says Erin Stewart, vice president of clinical development for Artera, a developer of multimodal AI (MMAI)-based prognostic and predictive cancer tests.

Dec. 8, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for Lunit INSIGHT Risk, a mammography-based five-year breast cancer risk prediction model. Potential clearance is expected in 2026.

A new study shows large increases in the use of computed tomography (CT) scans of the head in emergency departments across the United States from 2007 to 2022. The study, which was published on Nov.19, 2025, in Neurology, the medical journal of the American Academy of Neurology, also found disparities in use of head CTs by race, type of insurance and hospital location.

Dec. 1, 2025 — Rapid AI has released the inaugural episode of its original podcast, "Radiology Rewired."

The podcast tackles the topics that are shaping today’s radiology industry, from AI innovation and integration to workforce training and challenges, with interviews from some of the industry’s leading innovators and practitioners, like:

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now